Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Operating Leases (2019 - 2025)

Spero Therapeutics' Operating Leases history spans 7 years, with the latest figure at $939000.0 for Q4 2025.

  • For Q4 2025, Operating Leases fell 63.19% year-over-year to $939000.0; the TTM value through Dec 2025 reached $939000.0, down 63.19%, while the annual FY2025 figure was $939000.0, 63.19% down from the prior year.
  • Operating Leases reached $939000.0 in Q4 2025 per SPRO's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $6.7 million in Q1 2021 to a low of $939000.0 in Q4 2025.
  • Average Operating Leases over 5 years is $4.1 million, with a median of $4.3 million recorded in 2023.
  • Peak YoY movement for Operating Leases: surged 47.38% in 2021, then crashed 63.19% in 2025.
  • A 5-year view of Operating Leases shows it stood at $6.0 million in 2021, then fell by 17.01% to $5.0 million in 2022, then dropped by 22.84% to $3.8 million in 2023, then crashed by 33.31% to $2.6 million in 2024, then plummeted by 63.19% to $939000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Operating Leases are $939000.0 (Q4 2025), $1.5 million (Q3 2025), and $1.8 million (Q2 2025).